|
Market Closed -
Nasdaq
00:00:00 11/09/2026 +04
|
5-day change | 1st Jan Change | ||
| 2.500 USD | +0.81% |
|
-5.66% | +16.82% |
| 09-08 | Veru Advances Oral Sabizabulin into Planned Phase 2 Clinical Trial for Daraxonrasib Resistant Metastatic Pancreatic Cancer | CI |
| 08-10 | Veru Inc., Q3 2026 Earnings Call, Aug 10, 2026 |
Chart: Technical Analysis
NasdaqUSD
| Markets | Quality | ||
|---|---|---|---|
Nasdaq
| VERU | Delayed | |
CBOE
| VERU | Real-time |
Technical analysis trends
| Short Term | Mid-Term | Long Term | |
|---|---|---|---|
| Trend | Neutral | Neutral | Neutral |
| Resistance | 2.8 | 4.23 | 4.11 |
| Spread/Res. | -10.71% | -40.90% | -39.17% |
| Spread/Supp. | +8.23% | +19.62% | +19.62% |
| Support | 2.31 | 2.09 | 2.09 |
MarketScreener's Technical Analysis Ratings
| Short Term Timing | |
|---|---|
| Middle Term Timing | |
| Long Term Timing | |
| RSI | |
| Bollinger Spread | |
| Unusual Volumes |
- Stock Market
- Stocks
- VERU Stock
- Charts Veru Inc.
Select your edition
All financial news and data tailored to specific country editions
